Neovasc Comments on European Heart Journal Publication
28 April 2022 - 3:05PM
via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company")
(NASDAQ, TSX: NVCN) today announced that the European Heart Journal
has published an article entitled, “Impact of the Coronary Sinus
Reducer on Absolute Blood Flow and Microvascular Resistance Case
Report.” The article, authored by Francesco Giannini, M.D., Maria
Cecilia Hospital, Cotignola, Italy, describes objective
improvements in the amount of oxygenated blood delivered to the
heart muscle in two patients suffering from refractory angina
treated with the Neovasc Reducer™ (“Reducer”).
The first patient was a 58-year-old male with a history of
coronary bypass surgery and multiple stenting procedures. Despite
several attempts to relieve his chest pain, the previous procedures
were not effective. The second patient was a 78-year-old male
suffering from a blocked stented vessel and recurrent chest pain.
Both patients had tried medicines to alleviate their pain but
remained symptomatic.
“Our findings are an important step forward in the treatment of
patients with refractory angina and microvascular dysfunction,”
said senior author Julien Adjedj, MD PhD, Department of Cardiology,
Arnault Tzanck Institute, Saint Laurent-du-Var, France. “For the
very first time, we see real-time improvements in objective
measures of microvascular dysfunction in patients suffering from
refractory angina that have been implanted with the Reducer.”
The physicians measured the changes in absolute coronary blood
flow and microvascular resistance in real time using continuous
thermodilution while implanting the Reducer. Upon implantation, the
physicians observed an improvement in coronary blood flow in both
cases, from 100 to 148mL/min for the first patient and from 107 to
133mL/min for the second patient. Measures of microvascular
resistance also improved.
Fred Colen, President and Chief Executive Officer of Neovasc,
added, “It’s gratifying to see such promising, objective data
targeting this large group of patients that have no other good
options. These data, coupled with other ongoing prospective studies
may provide important insights into the Reducer’s mechanism of
action and potential benefits for patients with microvascular
dysfunction.”
About Reducer
The Reducer is CE-marked in the European Union for the treatment
of refractory angina, a painful and debilitating condition that
occurs when the coronary arteries deliver an inadequate supply of
blood to the heart muscle, despite treatment with standard
revascularization or cardiac drug therapies. Reducer is
investigational in the United States in the COSIRA-II clinical
trial. Refractory angina, resulting in continued symptoms despite
maximal medical therapy and without revascularization options,
affects millions of patients worldwide, who typically lead severely
restricted lives because of their disabling symptoms. The Reducer
is designed to alter blood flow within the myocardium of the heart
and increase the perfusion of oxygenated blood to ischemic areas of
the heart muscle, which may provide relief of angina symptoms.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops,
manufactures, and markets products for the rapidly growing
cardiovascular marketplace. Its products include Reducer, for the
treatment of refractory angina, which is not currently commercially
available in the United States and has been commercially available
in Europe since 2015, and Tiara™ for the transcatheter treatment of
mitral valve disease, which is currently under clinical
investigation in the United States, Canada, Israel, and Europe. For
more information, visit: www.neovasc.com.
InvestorsMike CavanaughWestwicke/ICRPhone:
+1.646.877.9641Mike.Cavanaugh@westwicke.com
MediaSean LeousWestwicke/ICRPhone:
+1.646.866.4012 Sean.Leous@westwicke.com
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and applicable Canadian securities
laws that may not be based on historical fact. When used herein,
the words “expect”, “anticipate”, “estimate”, “may”, “will”,
“should”, “intend,” “believe”, and similar expressions, are
intended to identify forward-looking statements. Forward-looking
statements may involve, but are not limited to, the significance
and promising nature of the case report and the growing
cardiovascular marketplace. Forward-looking statements are based on
estimates and assumptions made by the Company in light of its
experience and its perception of historical trends, current
conditions and expected future developments, market and other
conditions as well as other factors that the Company believes are
appropriate in the circumstances. Many factors could cause the
Company’s actual results, performance or achievements to differ
materially from those expressed or implied by the forward-looking
statements, including those described in the “Risk Factors” section
of the Company’s Annual Report on Form 20-F and in the Management’s
Discussion and Analysis for the year ended December 31, 2021
(copies of which may be obtained at www.sedar.com or www.sec.gov).
These factors should be considered carefully, and readers should
not place undue reliance on the Company’s forward-looking
statements. The Company has no intention and undertakes no
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Neovasc (TSX:NVCN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Neovasc (TSX:NVCN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024